News

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Click through our slideshow to see a glimpse of what the 2025 Masterclasses in Dermatology conference has to offer.

Merz Aesthetics' global study reveals that aesthetic treatments boost self-confidence, social well-being, and self-perception beyond physical appearance.

Although the tool is currently designed for research use only, CEO Andy Beck, MD, PhD, is excited about its future in clinical dermatopathology.

Hispanic and non-White patients with psoriatic arthritis (PsA) had higher tender joint counts and greater disease severity, highlighting racial and ethnic disparities in PsA disease burden and treatment outcomes.

Patients treated with dupilumab showed significant reductions in disease severity, itch, and corticosteroid use.

Jonathan Zalevsky, PhD, discusses the unmet needs in atopic dermatitis treatment, the potential of Rezpeg, and the importance of novel therapies.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

A novel AI model was able to achieve 99.86% accuracy for diagnosing skin conditions, even in people with darker skin tones or excessive hair.

“I think some key things that stand out to me are that it's safe, effective, backed by rigorous clinical data, and has very high patient satisfaction,” Watchmaker said about the new product.

The overwhelmingly positive feedback from both clinicians and patients reinforces the unmet need roflumilast foam is addressing in seborrheic dermatitis care.

Recent research underscores the critical role of periorbital skin care in maintaining a youthful and healthy appearance across all ethnicities.

Jonathan Zalevsky, PhD, discusses the fundamentally different path of Rezpeg compared with existing IL-4 and IL-13 inhibitors in atopic dermatitis.

Michael Rubio, PA-C, and Renata Block, MMS, PA-C discuss the complexities associated with practicing telemedicine, especially as a PA.

New antiaging dermatology concepts target cellular senescence to slow aging and improve skin health with senotherapeutics.

Explore the top headlines of the week including the expanding role of NPs and PAs, a clinician’s guide to chemical peels, and recently announced therapeutic updates.

In case you missed it, this week we had news about rezpegaldesleukin’s fast track designation for AD, bimekizumab’s long-term efficacy for HS, conference recaps of SBS and MOPD, and more.

This week, we feature top articles from our sister publications on FDA approvals, top insights, and new data.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

A global review found that skin condition advocacy groups offer diverse mental health resources, but accessibility gaps persist worldwide.

The article highlights the immense global burden of atopic dermatitis, the most common chronic inflammatory skin disease, affecting over 200 million individuals worldwide.

Zalevsky shares insights into the implications of the designation and what it may mean for Rezpeg's development timeline.

Adelaide A. Hebert, MD, FAAD, stressed the importance of educating patients, setting realistic expectations, and ensuring they adhere to AD treatment plans.

Bimekizumab demonstrated long-term effectiveness in patients with HS, with over 85% maintaining response and reduced draining tunnels.

Michael Rubio, PA-C talks with Renata Block, MMS, PA-C, about his virtual care platform and how it can expand access to care.

Key 2025 tax law changes for dermatologists include expiring TCJA provisions, potential rate adjustments, and new deduction policies under Trump.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Renata Block, MMS, PA-C, and Michael Rubio, PA-C discuss the complexities of developing a telehealth program in the world of dermatology.

Explore 2025’s dermatology M&A trends, economic shifts, and key investment drivers shaping the industry's future.

The state-of-the-art facilities in California, Georgia, and Texas will expand AMI’s curriculum to providers of all levels.